Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

October 31, 2009

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

bortezomib

1.3 mg/m\^2 on days 1, 4, 8, 11

DRUG

bendamustine

90 mg/m\^2 days 1 and 4

DRUG

rituximab

375 mg/m\^2 day 1

Trial Locations (3)

10021

Cornell Wiell Medical College, New York

14642

University of Rochester Medical Center (James P. Wilmot Cancer Center), Rochester

68198

Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Cephalon

INDUSTRY

lead

University of Rochester

OTHER

NCT00547534 - Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter